Skip to main content

Reviewing Evidence for Therapies in NSCLC With EGFR Exon 20 Insertion

*October 2022*

During a Targeted Oncology case-based roundtable discussion, Zofia Piotrowska, MD, MHS, discussed the data from clinical trials supporting mobocertinib and amivantamab for patients with non–small cell lung cancer and an EGFR exon 20 insertion mutation. Read more.